NEW YORK (GenomeWeb News) – Sequencing technology firm PathoGenetix has raised $3.6 million, it said in a regulatory filing.

In the document filed with the US Securities and Exchange Commission on Tuesday, the Woburn, Mass.-based firm said it is targeting $9.1 million in the current offering. The type of securities being offered is in the form of equity. The company did not identify the investors or say how it plans to use the funding.

A company official did not respond to an e-mail requesting comment.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A report from MIT identifies areas of scientific research where declining research support is hindering needed advances.

In PLOS this week: phylogenetic study of hepatitis E viruses in Swedish moose, recombination sites in the honeybee genome, and more.

Differences in DNA methylation could be used to distinguish between DNA samples obtained from identical twins, researchers say.

A retrovirus that's been integrated into the human genome appears to have a role in embryonic development, researchers report.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.